Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19257311 | 0.82 | DNM1 (0.31) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29581157 | 0.77 | CA12 (0.38) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29581908 | 0.77 | CA12 (0.38) | CA12CA2CA3CA4CA6 | |
| SCHEMBL19248308 | 0.77 | CA12 (0.38) | CA12CA2CA3CA4CA6 | |
| SCHEMBL9288725 | 0.74 | TSHR (0.32) | — | |
| SCHEMBL82581 | 0.72 | CA12 (0.57) | CA12CA2CA3CA4CA6 | |
| SCHEMBL12794518 | 0.72 | CA12 (0.57) | CA12CA2CA3CA4CA6 | |
| SCHEMBL15444951 | 0.72 | CA12 (0.57) | CA12CA2CA3CA4CA6 | |
| SCHEMBL8854164 | 0.70 | DNM1 (0.36) | CA12CA9 | |
| SCHEMBL10607367 | 0.70 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190203047-A1 | Antithrombotic Compounds, Methods and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-04 | — | — | US | disclosed |
| US-10202507-B2 | Antithrombotic compounds, methods and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-12 | — | — | US | disclosed |
| US-20170233573-A1 | Antithrombotic Compounds, Methods and Uses Thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233573-A1 | Antithrombotic Compounds, Methods and Uses Thereof | SELP, F2, FGB | CA12 2783/4885CA2 2375/4885CA3 1348/4885 |
| US-20190203047-A1 | Antithrombotic Compounds, Methods and Uses Thereof | SELP, F2, SERPINC1 | CA12 2848/4885CA2 2607/4885CA3 1485/4885 |
| US-10202507-B2 | Antithrombotic compounds, methods and uses thereof | SELP, F2, FGB | CA12 2783/4885CA2 2375/4885CA3 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.